METHENAMINE HIPPURATE | A205661 | AUROBINDO PHARMA LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Pharmobedient Consulting, LLC FDA-2025-P-3709 · 8 docket documents Pharmobedient Consulting, LLC filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Methenamine Hippurate Tablets 500 mg suitable for submission in an Abbreviated New Drug Application, with the Reference Listed Drug bei | Suitability | 2025-09-11 | Withdrawn | Pharmobedient Consulting, LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.3147
per ea
Lowest NADAC/Unit
$0.3147
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 65862078201METHENAMINE HIPP 1 GM TABLET | $0.3147 | EA | Generic | — | 2026-06-17 |
| 72603081601METHENAMINE HIPP 1 GM TABLET | $0.3147 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.